Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 1.00 |
| ▸ | CNR2 | P34972 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.92 |
| ▸ | RGS12 | O14924 | 1/20 | 0.92 |
| ▸ | GMNN | O75496 | 1/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
| ▸ | THPO | P40225 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Win-552122 SCHEMBL29611661 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29361053 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29410177 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29381882 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL118531 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL10093015 | 1.00 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL31338445 | 0.98 | CNR1 (0.96) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL1517636 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL8071465 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 | |
| Win-552122 SCHEMBL29496357 | 0.96 | CNR1 (1.00) | CNR1CNR2ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | claimed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| WO-2007125049-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-5112820-A | Vision defects | STERLING DRUG INC. (US) | 1992-05-12 | — | — | US | claimed |
| WO-1990007505-A1 | 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL-2,3-DIHYDROPYRROLO[1,2,3-de]-1,4-BENZOXAZINES | STERLING DRUG INC. (US) | 1990-07-12 | — | — | WO | claimed |
| US-4939138-A | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | claimed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130123356-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20040266861-A1 | Use for the treatment of gastroesophageal reflux disease | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1453497-A1 | USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | AstraZeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003043619-A1 | NEW USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | ASTRAZENECA AB (SE) | 2003-05-30 | — | — | WO | disclosed |
| EP-0833818-B1 | 3-ACYLINDOLES AS CB2 RECEPTOR AGONISTS | SANOFI SYNTHELABO (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-1990007505-A1 | 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL-2,3-DIHYDROPYRROLO[1,2,3-de]-1,4-BENZOXAZINES | STERLING DRUG INC. (US) | 1990-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | CNR1 25/4885CNR2 26/4885ALDH1A1 4349/4885 |
| US-20130123356-A1 | MODULATOR | MRGPRX2, NR3C2, MC2R | CNR1 90/4885CNR2 82/4885ALDH1A1 1637/4885 |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR1 2/4885CNR2 1/4885ALDH1A1 3168/4885 |
| US-20040266861-A1 | Use for the treatment of gastroesophageal reflux disease | CNR2, CNR1, HRH2 | CNR1 2/4885CNR2 1/4885ALDH1A1 2187/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.